Navigation Links
InVitria's Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin

SACRAMENTO, Calif., Oct. 23 /PRNewswire/ -- InVitria has released data that shows that Lacromin, a recombinant growth factor for cell culture media outperforms transferrin and provides a cost-effective solution to rising transferrin costs. Because Lacromin is produced in a completely animal-free system, it provides improved productivity and safety over animal-derived alternatives including bovine and human transferrin. In addition data has shown that Lacromin significantly increased the productivity of antibody production when compared with these other sources of transferrin.

"We are excited about Lacromin and its success as safer, more productive replacement for transferrin," said Victor Hicks, Vice President and Commercial Director, InVitria. "Lacromin(TM) provides a cost-effective solution to the challenge of rising transferrin costs and increasing concern over the use of animal-derived ingredients in cell culture. Given the FDA's preference for non-animal derived cell culture media ingredients, animal-free recombinant proteins like Lacromin(TM) are a real breakthrough for this market."

InVitria markets Lacromin(TM) to customers that seek a serum-free and animal component free cell culture media source for their biopharmaceutical production.

About Lacromin(TM)

Lacromin(TM) is recombinant human lactoferrin derived from plants. Lacromin(TM) holds many advantages over current cell culture media ingredients:

-- Strong growth factor

Lacromin(TM) has been shown to promote cell growth in many cell lines,

including Chinese Hamster Ovary (CHO) cells and Mouse Hybridoma cells.

-- Outperforms Transferrin

Lacromin(TM) promotes higher cell density and reduces cell doubling

time when compared with Transferrin.

-- Replaces Animal Derived Transferrin

Since Lacromin(TM) is derived from plants, it is free of any viral or

prion contaminant risks.

-- Improves IgG Productivity

In Hybridoma cells, Lacromin(TM) increased IgG productivity by 50%

versus Transferrin and by 6% versus Fetal Bovine Serum (FBS).

About InVitria

InVitria is a global supplier of animal-free products for use in bioprocessing, excipients, research and diagnostics.

InVitria's mission is to develop and supply our customers with products that deliver faster time to market, enhanced productivity, and improved safety.

For more information about InVitria, see our website at

Or Contact:


Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
2. Transgenic Animals
3. Bifidobacterium animalis
4. Bifidobacterium animalis
5. The QIAGEN Guide to Animal Cell Culture
6. The QIAGEN Guide to Animal Cell Culture
7. The QIAGEN Guide to Animal Cell Culture
8. The QIAGEN Guide to Animal Cell Culture
9. The QIAGEN Guide to Animal Cell Culture
10. The QIAGEN Guide to Animal Cell Culture
11. An Animal-Free DNase I
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier ... models, has promoted Melanie Aregger to serve as Chief Operating Officer. , ... the management team and was promoted to Head of InSphero Diagnostics in ...
(Date:11/24/2015)... 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) ... Pierre Laurin , President and Chief Executive Officer of ... Piper Jaffray 27 th Annual Healthcare Conference to be ... 2015. st , at 8.50am (ET) and ... the day. The presentation will be available live via a ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/24/2015)... YORK , November 24, 2015 ... in a European healthcare ... which the companies will work closely together in identifying European ... unmet medical need. The collaboration is underpinned by a significant ... fund. This is the first investment by Bristol-Myers Squibb in ...
Breaking Biology Technology:
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
Breaking Biology News(10 mins):